CP
DGX icon

Camelot Portfolios’s Quest Diagnostics DGX Stock Holding History

Camelot Portfolios’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,171
Closed -$255K – 208
2020
Q1 		$255K Buy
3,171
+643
+25% +$66.6K 0.14% 160
2019
Q4 		$270K Buy
2,528
+318
+14% +$33.2K 0.11% 185
2019
Q3 		$237K Buy
+2,210
New +$227K 0.11% 185
2019
Q2 		– Sell
-2,855
Closed -$257K – 241
2019
Q1 		$257K Hold
2,855
– – 0.11% 200
2018
Q4 		$238K Sell
2,855
-70
-2% -$6.56K 0.11% 185
2018
Q3 		$316K Buy
2,925
+1,000
+52% +$110K 0.14% 156
2018
Q2 		$212K Buy
+1,925
New +$201K 0.09% 186
2017
Q4 		– Sell
-2,852
Closed -$267K – 191
2017
Q3 		$267K Sell
2,852
-8
-0.3% -$849 0.13% 138
2017
Q2 		$318K Sell
2,860
-34
-1% -$3.6K 0.16% 120
2017
Q1 		$284K Buy
+2,894
New +$276K 0.14% 139

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Camelot Portfolios's DGX Position: Q2 2020 in Review

Camelot Portfolios sold out of Quest Diagnostics (DGX) in Q2 2020, closing a stake of 3,171 shares — an estimated $255K sold.

Camelot Portfolios first reported a position in DGX in Q1 2017 and held it in 10 quarters. The position peaked at $318K in Q2 2017. 748 funds tracked by Wall St. Rank hold DGX as of Q2 2020.

  • Camelot Portfolios reported no remaining Quest Diagnostics position as of Q2 2020 after selling out during the quarter.
  • Camelot Portfolios sold 3,171 Quest Diagnostics shares in Q2 2020, an estimated $255K.
  • Camelot Portfolios first reported a position in Quest Diagnostics in Q1 2017 and held it in 10 quarters.
  • Camelot Portfolios's Quest Diagnostics position peaked at $318K in Q2 2017.
  • 748 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2020.

Based on Camelot Portfolios's 13F filing for Q2 2020, filed 30 Jul 2020.